Davison DK - Search Results

1

Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.

Veazey RS, Ketas TA, Klasse PJ, Davison DK, Singletary M, Green LC, Greenberg ML, Moore JP. Veazey RS, et al. Among authors: davison dk. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10531-6. doi: 10.1073/pnas.0802666105. Epub 2008 Jul 22. Proc Natl Acad Sci U S A. 2008. PMID: 18647836 Free PMC article.

2

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.

Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. Dwyer JJ, et al. Among authors: davison dk. Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. doi: 10.1073/pnas.0701478104. Epub 2007 Jul 19. Proc Natl Acad Sci U S A. 2007. PMID: 17640899 Free PMC article.

3

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.

Sista PR, Melby T, Davison D, Jin L, Mosier S, Mink M, Nelson EL, DeMasi R, Cammack N, Salgo MP, Matthews TJ, Greenberg ML. Sista PR, et al. AIDS. 2004 Sep 3;18(13):1787-94. doi: 10.1097/00002030-200409030-00007. AIDS. 2004. PMID: 15316339 Clinical Trial.

4

Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure.

Bai X, Wilson KL, Seedorff JE, Ahrens D, Green J, Davison DK, Jin L, Stanfield-Oakley SA, Mosier SM, Melby TE, Cammack N, Wang Z, Greenberg ML, Dwyer JJ. Bai X, et al. Among authors: davison dk. Biochemistry. 2008 Jun 24;47(25):6662-70. doi: 10.1021/bi702509d. Biochemistry. 2008. PMID: 18507398

5

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.

Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML. Mink M, et al. J Virol. 2005 Oct;79(19):12447-54. doi: 10.1128/JVI.79.19.12447-12454.2005. J Virol. 2005. PMID: 16160172 Free PMC article.

6

Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency.

Dwyer JJ, Wilson KL, Martin K, Seedorff JE, Hasan A, Medinas RJ, Davison DK, Feese MD, Richter HT, Kim H, Matthews TJ, Delmedico MK. Dwyer JJ, et al. Among authors: davison dk. Protein Sci. 2008 Apr;17(4):633-43. doi: 10.1110/ps.073307608. Protein Sci. 2008. PMID: 18359857 Free PMC article.

7

Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.

Berman PW, Murthy KK, Wrin T, Vennari JC, Cobb EK, Eastman DJ, Champe M, Nakamura GR, Davison D, Powell MF, Bussiere J, Francis DP, Matthews T, Gregory TJ, Obijeski JF. Berman PW, et al. J Infect Dis. 1996 Jan;173(1):52-9. doi: 10.1093/infdis/173.1.52. J Infect Dis. 1996. PMID: 8537682

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7 results

Search Page

Filters